Drug Trial Radar · NCT06108219
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
175
Actual
Start
Oct 25, 2023
Primary completion
Feb 13, 2026
Study completion Aug 24, 2026
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions
Miricorilant (Cohort A)Drug
Miricorilant 100 mg for oral dosing
Placebo (Cohort A)Drug
Matching placebo for oral dosing for 48 Weeks
Miricorilant (Cohort B)Drug
Miricorilant 100 mg for oral dosing Miricorilant 200 mg for oral dosing
Placebo (Cohort B)Drug
Matching placebo for oral dosing for 24 Weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent relative change from Baseline in liver-fat content assessed by MRI-PDFF (Cohort A and Cohort B)Time frame: Week 24
Locations
77 sites in 3 countries. Site status is shown where the registry gives one.
Site #207
Chandler, Arizona
Site #209
Tucson, Arizona
Site #378
Huntington Park, California
Site #439
Lancaster, California
Site #469
Long Beach, California
Site #373
Los Angeles, California
Site #214
Panorama City, California
Site #233
Santa Ana, California
Site #452
Boca Raton, Florida
Site # 101
Gainesville, Florida
Site #465
Hallandale, Florida
Site #430
Hialeah Gardens, Florida
Site #458
Lakewood Rch, Florida
Site #475
Largo, Florida
Site #438
Miami Lakes, Florida
Site #460
Viera, Florida
Site #453
Houma, Louisiana
Site #451
Marrero, Louisiana
Site #061
Metairie, Louisiana
Site #440
Rockville, Maryland
Site #442
Saint Paul, Minnesota
Site #228
Kansas City, Missouri
Site #455
Jackson, New Jersey
Site #445
East Syracuse, New York
Site #454
New York, New York
Site #464
Morehead City, North Carolina
Site #447
Beavercreek, Ohio
Site #470
Columbus, Ohio
Site #448
Dayton, Ohio
Site #437
Westlake, Ohio
Site #461
Cordova, Tennessee
Site # 546
Arlington, Texas
Site #545
Austin, Texas
Site #211
Austin, Texas
Site #432
Brownsville, Texas
Site #370
Dallas, Texas
Site #213
Edinburg, Texas
Site #215
Edinburg, Texas
Site #431
Georgetown, Texas
Site # 066
Houston, Texas
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.